Good afternoon, ladies and gentlemen, and welcome to the STAAR Surgical fourth quarter 2020 financial results conference call. At this time, all participants are in a listen only mode. Thank you, operator. Good afternoon, everyone. Thank you for joining us on the STAAR Surgical conference call this afternoon to discuss the company's financial results for the fourth quarter and the fiscal year ended January 1, 2021. On the call today are Caren Mason, President and Chief Executive Officer, and Patrick Williams, Chief Financial Officer. The press release of our fourth quarter results was issued just after 4:00 P.M. Eastern Time, and is now available on STAAR's website at www.staar.com. Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and prospects. These statements are based on the judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the safe harbor statement in today's press release, as well as STAAR's public periodic filings with the SEC. Except as required by law, STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so. In addition, to supplement the GAAP numbers, we have provided non-GAAP adjusted net income and adjusted earnings per share and sales in constant currency. We believe that these non-GAAP numbers provide meaningful supplemental information and are helpful in assessing our historical and future performance. A table reconciling the GAAP information to the non-GAAP information is included in today's press release. Following our prepared remarks, we will open the line to questions from publishing analysts. We ask analysts limit themselves to two initial questions, then re-queue with any follow-ups. We thank everyone in advance for their cooperation with this process. With that, I would now like to turn the call over to Caren Mason, President and Chief Executive Officer of STAAR. Thank you, Brian. Good afternoon, everyone, and thank you for joining us on today's call. The fourth quarter and fiscal 2020 results we reported today are consistent with our January 11th pre-announcement and represent yet another year of record results, increased consumer awareness, and growing surgeon commitment to our proprietary EVO Visian family of implantable Collamer lenses. The COVID-19 global pandemic challenged our generally high levels of growth, particularly in the first half of 2020. However, for the second half of 2020, we were able to meet the original sales targets we entered the year with prior to the global pandemic taking hold in late January. 2020 demonstrated the continuing momentum of the industry shift towards our lens-based solutions for patients seeking visual freedom. In addition, in 2020, we launched a new presbyopic lens, EVO Viva, and made progress towards introducing our EVO family of lenses in the U.S. and introduced new programs to increase customer engagement. Our 2020 performance confirms our position as a consistent and rapidly growing innovative leader in the refractive industry. Turning now to the fourth quarter, ICL unit growth in the fourth quarter continued the rebound we saw in the third quarter as more of our markets more fully reopened. We achieved strong growth in several markets, including China up 17%, Japan up 52%, Germany up 28%, APAC distributor markets up 71%, and Latin America up 26%, all as compared to the prior-year quarter. We also saw a significant sequential improvement in India during the fourth quarter, where ICL units on a year-over-year basis were down just 10% in the fourth quarter of 2020 as compared to down 55% in the third quarter. The Middle East remained our most challenged market due to COVID-19 during the fourth quarter. For fiscal year 2020, ICL units were up 11% as compared to the prior year. Our positive ICL unit growth must be considered in the context of the global pandemic and also the total market for refractive procedures. Industry reports estimate a decline of 21% in total refractive industry procedures in 2020 as compared to the prior year. The chasm between STAAR's positive ICL unit growth rate, and the decline in total refractive industry procedures demonstrates that we are continuing to capture market share. Therefore, while our growth in certain markets remains impacted by COVID-19, our enthusiasm for even brighter days ahead is bolstered by solid second half results in 2020 and a solid start to 2021. Our strategic imperative remains to position our EVO ICL family of implantable lenses as a transformational pathway to visual freedom for patients seeking a life independent of glasses and frequent replacement contact lenses. Our strategies support the transformation to a lens-based future for refractive vision correction, and should allow STAAR to capture a disproportionate share of the 5.8 million annual refractive procedures that industry market reports project in 2025. Today, and as we look ahead, we are laying the foundation for a STAAR that can grow from selling hundreds of thousands of lenses per year to millions of lenses per year through increasing consumer awareness, surgeon commitment, new product introductions, and appropriate investments to scale the company consistent with our significant growth opportunity. I will briefly touch on each of these areas to illustrate our focus and commitment. First, we have increasing evidence that our multi-channel consumer awareness and marketing activities globally are showing positive results. Where we promote the exceptional desirability of our EVO ICL family of lenses to consumers, we see great enthusiasm among consumers on social media, more visits by consumers to our doctor finder, and higher ICL unit growth, including in China, Japan, Korea, and Germany, to name a few. EVO Visian ICL patient influencers from television or music personalities to everyday people are creating meaningful interactions with their followers on various social media platforms such as TikTok, Little Red Book, and Instagram that result in these followers becoming prospective patients. Our investment in consumer marketing is supported by marketing research that shows 40-point plus upticks in ICL interest in key markets when consumers understand the advantages of our ICL lenses, including removability, no dry eye syndrome, and excellent night vision. This same marketing research shows a 60-point increase in interest among U.S. consumers. Second, we are gaining increasing surgeon commitment with our lenses, which is supported by clinical validation. 2020 is the first year STAAR sold more lower diopter lenses between -0.5 and -10 than higher diopter lenses between -10 and -20. Our opportunity with surgeons includes training and certifying more refractive surgeons globally, and also increasing the number of ICL lenses implanted by currently certified surgeons. Increasing lens utilization remains a significant growth opportunity for STAAR as surgeons can move from implanting tens of lenses per year to hundreds or even thousands, as we've seen in certain Asian markets. Turning to a third strategic priority, which is introducing our innovative products to large and new markets globally, we are continuing the controlled rollout of our EVO Viva presbyopia lens in Europe. The initial commercial surgeons are implanting the Viva lens while gaining valuable insights for delighting patients at each distance, near, intermediate, and far. These insights will be part of the EVO Viva playbook of best practices that we will share with certified surgeons during full commercialization of the lens expected in the second half of 2021. In the coming weeks, we will add more surgeons as part of our phased rollout of the Viva lens. In the U.S., we have implanted all patients in the study for our EVO family of myopia lenses, and follow-up is being conducted per the trial protocol. Our plan remains to submit the data to the FDA for marketing approval in late April. We will provide an update on the status of our submission and any other details when appropriate and permitted. The U.S., as the number two market in the world for refractive procedures, has long been a market where we looked forward to introducing our family of EVO lenses. We believe we remain on track, pending FDA approval, to introduce our EVO lenses to the U.S. market in the fourth quarter of this year. Finally, we continue moving forward with scaling the company to meet increasing demand and position STAAR to sell millions of lenses in the future. Capital investments include the following. Establishment of our EVO manufacturing operations in Nidau, Switzerland, and our advanced presbyopia Viva lens manufacturing facility in Lake Forest, California. Also expanding capacity of our Monrovia manufacturing facility. Operating investments include scaling our revenue generating sales and marketing teams and programs. We have recently added key hires to the U.S. sales team and will continue to support our growth in China with additional in-country STAAR account executives. We will also invest in marketing programs in geographies that can demonstrate strong returns by driving higher levels of ICL unit growth. Before turning the call over to Patrick, let me conclude my prepared remarks by welcoming two new members to the STAAR Board of Directors, Dr. Elizabeth Yeu and Dr. Peony Yu, who joined the board as previously announced on January 21st. I would also like to thank retiring board member John Moore for his more than decade of service to STAAR. Patrick. Thank you, Caren, and good afternoon, everyone. Total net sales at Q4 2020 were $46 million, up 18%, as compared to the $38.9 million of net sales in Q4 2019 and down 2% on a sequential basis from Q3 2020. The year-over-year increase in net sales was attributable to the growth Caren highlighted earlier. The sequential decrease in sales was due to the moderate seasonality in our business. As a reminder to our investors and analysts, Q1 and Q4 have historically represented our seasonally lowest quarters, and thus, we continue to believe Q1 2021 will be slightly down from our Q4 2020 results. In terms of product mix, ICL sales represented 87% of total company net sales for the fourth quarter of 2020, and other products represented 13%, which is consistent with recent trends. Gross profit for Q4 2020 was $34.3 million, or 74.6% of net sales, as compared to gross profit of $28.8 million, or 74.1% of net sales for Q4 2019, and $34.9 million or 74.1% of net sales for Q3 2020. The 50 basis point increase in gross margin as compared to Q4 2019 is primarily due to geographic sales mix, partially offset by inventory reserves taken on certain lower margin IOL products which are being discontinued in manufacturing projects. The sequential increase in gross margin from the third quarter is due to sales mix, partially offset by inventory reserves taken on certain lower margin IOL products which are being discontinued. We expect Q1 and fiscal year 2021 gross margins to be similar or slightly up from our Q4 2020 results. Moving down the income statement, total operating expenses for Q4 2020 were $30.2 million as compared to $26.5 million in Q4 2019 and $30 million for Q3 2020. Taking a closer look at the components of operating expenses, G&A expense for Q4 2020 was $9.5 million compared to $7.9 million for Q4 2019 and $8.6 million for Q3 2020. The year-over-year increase in G&A is due to increased salary related costs, variable compensation, corporate insurance, and facilities costs. The increase from Q3 2020 was due to increased variable compensation, corporate insurance, and salary related costs. We expect G&A dollars for Q1 2021 to be slightly higher than Q4 2020 and to continue at a similar level of absolute dollars each quarter for the balance of 2021. Selling and marketing expense was $11.8 million for Q4 2020 compared to $11.2 million for Q4 2019 and $12.6 million for Q3 2020. The increase in selling and marketing expense from the prior year was due to increased salary related costs and advertising and promotional expenses, partially offset by decreased travel and sales meetings and trade shows expenses. The decrease from Q3 2020 was due to decreased advertising and promotional expense, partially offset by increased salary related costs and variable compensation. We expect selling and marketing as a percent of sales to represent approximately 33% of sales for the first quarter and the full year of 2021 as the company makes appropriate investments in scaling the company consistent with Caren's comments earlier. Research and development expense was $9 million in Q4 2020 compared to $7.4 million for Q4 2019 and $8.8 million for Q3 2020. The increase in research and development expense as compared to the prior year quarter was primarily due to increased clinical expenses associated with our EVO clinical trial in the U.S. and increased variable compensation. The slight sequential increase in R&D is due to an increase in salary related costs, partially offset by lower clinical spending. We expect quarterly R&D for 2021 to remain similar to our Q4 2020 in absolute dollars, which should yield some leverage in R&D as a percentage of a higher level of anticipated sales throughout 2021. Operating income in Q4 2020 was $4.1 million or 8.8% of sales as compared to $2.3 million or 6% of sales for Q4 2019. The 280 basis point year-over-year expansion in operating margin is due to leverage on the fixed and variable operating expense during the quarter. Net income in Q4 was $3.3 million or $0.07 per diluted share compared to a net income of $6.4 million or $0.14 per share in Q4 2019. The lower net income in the fourth quarter of 2020 as compared to 2019 is due to a higher provision for income taxes as the result of a $0.07 per share tax benefit from our 2019 tax valuation release. On a non-GAAP basis, adjusted net income for Q4 2020 was $6.8 million, or $0.14 per diluted share, compared to adjusted net income of $5.5 million or $0.12 per diluted share in Q4 2019. A table reconciling the GAAP information to the non-GAAP information is included in today's financial release. Turning now to our balance sheet. Our cash and cash equivalents as of January 1st, 2021, totaled $152.5 million, up $24.2 million compared to $128.3 million at the end of the third quarter 2020. The sequential increase from the third quarter is primarily attributable to $19.6 million in cash generated from operations. As we look ahead in 2021, we anticipate increasing our CapEx investments as we continue investing in expanding our manufacturing capacity, footprint, scaling production for our new Viva lens, and infrastructure scalability. For the full year 2021, we anticipate a total CapEx spending to be in the range of $15 million - $20 million. Finally, STAAR will be participating in the Credit Suisse Virtual West Coast Investor Bus Trip on March 22nd, we look forward to speaking with many of you there. This concludes our prepared remarks. Operator, we are now ready to take questions. Thank you. At this time, I would like to inform everyone, in order to ask a question, please press star one on your telephone keypad. Again, that is star one to ask a question. We have your first question from Chris Cooley from Stephens. Your line is open. Good evening. Hope everyone is well. Just maybe I guess my first two, and then I'll hop back into you. When you think about the growth that you saw in the second half of the year, clearly a strong read down there, Caren, on the ICL front. Didn't hear just a reiteration of kind of the long-term targets. I realize we don't have guidance for 21 formally, but just when you think about unit growth longer term for the ICL, just curious if what you're seeing now still keeps those long-range plan targets within reach. Then what gives you confidence along that just off the base business? I've got a follow-up. Sure. Thank you very much, Chris. We definitely are very confident around momentum in the business, as obviously we're seeing a lot of the great trajectory in the second half of 2020 continue into 2021. When we look at our long-term commitment, three-year growth rate of 25% and 35% ICL unit growth by the end of 2022, we're very committed to achieving those growth levels. Ideally, as we look at 2021, we think about, obviously in the first half, very fine growth year-over-year. We talked a little bit about when we look at sequential growth will retain a seasonality, but when we look at year-over-year growth, especially in the first half, it could be very healthy. As we project in the second half of the year, we have a number of opportunities, either with EVO Viva addition and in the fourth quarter with EVO in the U.S., to even add on to what we think will be very healthy growth in 2021. I appreciate that. Hey, Chris, maybe I can just add something with our prepared remarks that we said it will give hopefully a very strong signal of our longer-term confidence. I talked about the CapEx spend, where we are increasing it in 2021 is a really scaling year for us or a scalability year of about $15 million-$20 million, which is about two times of what we did in 2020. Hopefully that's another strong signal by us that we have a lot of confidence in where we think this business can go over the next several years. No, that's great. I appreciate it. Just for my second question, Patrick, I really appreciate all the granularity you provided down to the middle of the income statement and also as it pertains to the growth line as we think about 2021, it really helps. I'm curious, though, as you make these understandable investments in infrastructure and personnel, getting ready for the launch of EVO in the fourth quarter here in the United States and obviously the continued ramp-up of Viva abroad, and then hopefully here in the U.S. shortly thereafter. When we exit 2021, I'm just curious, are we at the spend rate or I should say, is the company at the spend rate at that point where you can start to drive leverage, or is that just the initial kind of push and you'll need to further continue that kind of operating spend step up in the year thereafter as we think about building out the commercial infrastructure here in the U.S. and it sounds like China as well now. Thank you. Sure. It's a good question, and certainly Caren can add on. I think it's a little early for us to give, I would say, some of those longer-term projections since we're awaiting the U.S. approval, and we're starting to see the penetration within some of the other markets, including getting our beginnings of Viva right in Europe and then hopefully as we spread that out throughout the world. I think what you've seen in the model is that it's a fairly simplified model leveraged on a fairly nominal, what I would say revenue scale compared to peer groups or other medical device companies that are in a high-growth stage like we are. I'm very confident in our ability to have expansion. I would expect you will see expansion as we move forward through the years. We've got a nice tailwind related to our gross margins as a relation to geography mix. As a reminder, with the U.S. coming on board, it will be a direct market. It's one of the larger or more premium markets out there from an ASP standpoint. We're going to get a nice tailwind over the next several years related to building out that market. Some of the other direct markets as well, including Viva, which is right now a premium product for us compared to our current EVO lens. That does not keep me up at night, any sort of operating margin expansion, so we feel very good about the ability to move forward. With all that said, we will hold off, and know people are eager to see kind of what does this look like since our last Investor Day. We're looking forward to doing an Investor Day at some point in the not-so-distant future. You can expect we'll give some future looks, not only on the sales side, but through some of the leverage in P&L. We have your next question from Anthony Petrone from Jefferies. Your line is open. Thanks. Good afternoon, everyone. I hope everyone's staying healthy. A couple questions, one would be on Viva, one on U.S. EVO, and then one for Patrick just on distributor trends. On Viva, maybe just an update on expectations for the full-scale European launch at the European Cataract meeting later this year. What are the latest thoughts there, just as we continue to navigate COVID-19? That'll be question one. More so, what does that full-scale launch look like? Will there be more direct sales reps added ahead of that? Also in regards to DTC, will you ramp that up ahead of the ESCRS meeting in later this year? The second question on EVO timelines would be similar. Should we expect a ramp in DTC and sales force ahead of that? Then I'll have a follow-up for Patrick. Thanks. Okay. Thanks for joining us, Anthony. When we think about Viva in Europe, our goal is to continue to add surgeons who are certified and doing very well with our EVO myopia lenses throughout Europe over the next six-plus months. During that time, we continue to add, which we've already begun. We already have initial commentary on what works and what we can advise surgeons to do to well prepare patients for their expected vision, near, intermediate, and distance. We should have that playbook ready to go for all surgeons who are in approved markets, probably by, I would say, September. We were thinking of doing an experts meeting, which we do every year, a few days before ESCRS, having the Viva lens and playbook being the primary discussion points with surgeons on the podium who would be able to share their pearls as well as the patient experience and the direct-to-consumer experience. We're hesitating a bit on the timing, not because we won't be ready, but because we're really not sure yet whether the Amsterdam meeting is going to take place in terms of an in-person meeting rather than virtual. We would really prefer to roll this out if we can, either in a combined hybrid virtual in-person meeting or an in-person meeting. There's so much to share. When you're at one of our experts meetings and there are 350 people in the room and everyone's trying to grab the microphone to share their experiences, it's truly exciting and something we think Viva deserves. We'll see exactly what the timing will be of the experts meeting to roll out Viva with our leading surgeons around the world in approved markets. With regard to adding salespeople, we definitely are adding indirect markets, and we have been very, very good at building new hybrid markets such as Benelux, France, and Italy. We have done a good job of upgrading distributors who are now Sakura. All three, direct, hybrid, and distributors will be managing the Viva rollout. In terms of EVO in the U.S., we have a full rollout plan that is already in approval phases. We have been hiring people in the U.S. who are really strong in strategic account management. We have a number of exceptional programs that we'll be rolling out that have been very successful in Europe and in China, both from social media, from digital marketing, as well as testimonials and individuals who are very well respected to share their Viva, excuse me, their EVO experience. The U.S. will be an exceptional market, we believe, for consumer outreach. In each of the markets in the United States where we will be rolling out the EVO lens with significant and strong partners who are strategic partners of STAAR, who are KOLs, who are in big practices with lots of refractive procedures a year, all of that is being planned to be ready and available for fourth quarter. Thank you so much. If I can, just for Patrick, can you maybe walk us through how distributor destocking, restocking kind of played out exiting 2020, and how those trends will play out in the first half of 2021? Thank you so much. Yeah. We got quite a few questions about that, and I think what everyone needs to take away is that there's no unusualness to the business from stocking, de-stocking, et cetera. What we see at the end of the year is what I would call a normal pattern of the business, where some of the distributors are looking to make sure that their levels are appropriate across the different SKUs, right? They're really looking to right set that. We saw a little bit of that in some of the larger distributors like we have in China, the single one we have there. People shouldn't read any more into that. We're a normal course of business. We're moving forward. There's a lot of momentum in the business right now. Everyone's ordering direct markets, distributor markets, et cetera. Everything is really running at a normal pattern. Thank you. Of course. We have your next question from Brian Weinstein from William Blair. Your line's open. Hi, good afternoon. This is Andrew on today. Thanks for taking the question. Maybe we can start on U.S. market dynamics here. Caren, you've sort of always talked about the core demographics for EVO in Asia as sort of being that bucket of, I'll call them young professionals with a higher level of disposable income. Maybe as we think about the U.S. market here, can you just give us a little bit of an idea of how you view the demographic here for that product? As a corollary to that, any differences in how we should be thinking about maybe some consumer or macro sensitivity to the product here versus other areas around the globe? Thank you for joining us, Andrew, and answer to your question, yes, we do believe the demographic holds globally. 21 through 35-year-olds, many of whom daily contact lenses and glasses more than they would like. The strong interest in having visual freedom so they are able in the workplace, through exercise, sports, and outdoor activities, just be totally free to do whatever they need to do without any dependence on a visual correction apparatus. We expect that to continue and to be very strong. We believe that the U.S. consumer is especially interested in lenses that have such great benefits, such as the ability to be upgraded, the fact that there is no dry eye syndrome, the fact that there's exceptional night vision, and also an estimation that this is quiet in the eye and biocompatible. I think with all of these tremendous strengths, which are picked up so beautifully in social media around the world as really excited and happy recipients of the EVO lenses love sharing their stories. We expect it to happen in the U.S. and maybe even be more aggressive, in that we have the greatest consumers in the world in the United States. I think that in terms of going forward, our enthusiasm for being prepared and ready for a consumer world in the United States that becomes aware of EVO, I know that we're there. Great. Thank you. That was very helpful. I guess maybe a question on cash here. Obviously, what a difference a couple of years makes for you guys, and certainly congrats to the team for all the cash flow generation over the last couple of years. I guess with over $150 million sort of on the balance sheet and recognizing, Patrick, you gave a lot of good color on the internal investments here. We did notice that shelf that you have. I guess bringing it out bigger picture here, can you talk maybe some longer-term strategic functions that you might be investing in behind what you've outlined today, or even maybe some thoughts on M&A that might make you want to tap into that shelf? Thanks for the question. Yeah, no, great question, actually, guess kind of glad you brought it up. People should not be reading into the shelf other than that's just good corporate governance. Public companies should have a shelf that's registered and current at all times. That would be my response related to the shelf. In terms of capital deployment, et cetera, in my short time here, you can look back, the company has done just an incredible job of generating nice cash flow. Once again, what I consider to be off of a smaller revenue base compared to other high-growth companies. I think that's an attestation to the discipline that we have in making good investments, as well as the simplicity and beauty of the model that we have and our ability to penetrate. We'll continue to make investments primarily in the sales and marketing side, as we talked about, to drive market share, we will continue to believe that we can generate the cash. At this point, we've got a healthy balance sheet, no debt to speak of, and we're in a good space to grow our business organically. I think from that standpoint, that'll be our answer unless something else pops up. We've got early innings in terms of where we're at in the EVO business. We're very excited and have the capital means to support that. We have your next question from Bruce Jackson from The Benchmark Company. Your line's open. Hi. Good afternoon. Thank you for taking my question. I'd like to go back to a comment you made during your prepared remarks about the product mix now being tilted more towards the low diopter lenses. I was wondering if you got there with any actions in price or promotion, and what other further actions you might take to get more of a low diopter mix because you're coming up against the LASIK procedures where price might become a factor. I'd like to get your thoughts just generally on that. Sure. Thank you, Bruce, for joining us. In terms of what we have done over the past few years to encourage the lower diopter ranges for our refractive patients. First of all, on the pricing front, for spheric lenses only did have lesser cost associated with those lenses for the surgeon with their choice as to whether or not they wanted to pass that advantage onto a patient to further encourage them to go with lens rather than a LASIK procedure. At the same time, and I think this is really important, a number of our strategic partners around the world and KOLs did clinical validation studies and presented papers about the fact that the lower diopter patient is equally well-served as the higher diopter patient with outstanding results. We also made sure that in the societies in major countries, which we talked about before, such as Japan and Germany, the standard of care has really then reflected these changes in practice patterns for lens-based practices by moving approval levels from maybe a - 8 or a - 9 down to - 3, and in certain instances, down to a - 0.5. It is a combination of clinical validation, backing by the leading KOLs with papers in society, standard of care, and then by properly pricing to incentivize the surgeon and the patient to look at the ICL as always premium and primary and will be more expensive than laser vision. We believe deservedly so, but narrowing the gap a bit. Okay. That's great. Very helpful. If I could just get one more question in about China. Coming out of the Chinese New Year, if you could just give us a little color around how things are developing and how it relates versus your plan for the year. We're very excited about China's continuing enthusiasm with our lens. As a result of that, yes, after Chinese New Year, we already are picking up to levels at or above where we were pre. Our growth trajectory in China to be very strong. We're very excited about Q1 and getting ready for the real busy season in Q2 and Q3. Things are just going very well in China. All right. Fabulous. Thank you very much. Thank you. We have your next question from Ryan Zimmerman from BTIG. Your line's open. Yeah. Thanks for taking the questions. Appreciate it. Just maybe to follow up around some of the pricing trends. It was up about a little over 5%, I think, and just some of the best we've seen in a while. Patrick, maybe if you want to chime in, just how to think about pricing into 2021, and what was the result in the quarter here. Was it a function of geography, of lens type, maybe more torics? Just help us understand that and maybe how you think that plays out, particularly in 2021 with all of the new products that you are potentially introducing really in the later part of the year. Yeah, sure. Oh, go ahead, Caren. Sorry. I'll take it. Yeah. Where we really are is that toric is becoming a bigger part of mix in almost every market. There's just tremendous enthusiasm in bringing patients who have traditionally, and to this day, not had very good options with any, if they need a toric lens. We're getting a lot of demand, even more than usual in Asia as percentage. In some cases, we're moving beyond 47% - 50% or above 50% for torics. That obviously benefits us in terms of ASP. In terms of price around the world, we are marketing based on what we think is the value story. We also work very diligently with our partners on their strategic commitments. We ask our partners to grow their businesses in excess of 20% or 30%, on average, in terms of what they are going to commit to in return for a lot of what we provide. Definitely, in terms when you have mix and when you have much increasing volume, and a consistency around the way we sell and the way we reward, we expect this positive pricing trend to continue and advantage us in 2021. Okay. That's very helpful. I don't know if, Patrick, you have anything else to add on that one before I ask the other one. Nope. She covered it on the head. Okay. Great. Caren, just another one. With the EVO launch, over the course, really in the back half of 2021 in the U.S., given the number of physicians that are currently implanting Visian, how do you expect adoption to play out with EVO in the U.S.? Should this mimic how Viva is going right now, or do you expect all those physicians that are in the U.S. to adopt EVO, let's call it day one? Just trying to get a sense for how quickly out the gate you could have sales on that lens in the U.S. Different story with movement from Visian ICL without the central port to EVO Visian ICL versus Viva. Myopia and distance-only correction is straightforward, what we expect is that right out of the gate, there will be a number of surgeons who have either participated in a clinical trial, are already KOLs, who are already signed with strategic partners, or who have very successfully joined us in refractive restart over the last several months. We have surgeons who are committing to almost fully lens-based, others who expect that their percentage of laser vision correction procedures versus ICL procedures will flip. If they were 70/40 laser vision, it'll be 70/30 EVO. Expect a much faster adoption and a much stronger prospect at the gate with Viva. On purpose, because it is a multi-refractive correction procedure. It just, from every possible vantage point, we have a great lens like ours. We want to make this as simple as possible. Very few surgeons have done refractive presbyopia, so this is a whole new game to be able to do this wonderful lens without doing an inlay or a clip on the cornea. We are taking our time to have an extraordinary experience that all surgeons can handle Viva. Bottom line is, stay tuned with an FDA approval in the U.S., we expect to have a great launch. I'm showing no further questions at this time. I would now like to turn it back to Ms. Caren Mason, President and CEO, for any closing remarks. Thank you, operator. Thanks, everyone, for your participation on our call today. We look forward to speaking with many of you in the days and weeks ahead. We appreciate your interest and investment in STAAR Surgical. Please take good care, and all the best to all of you. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.